Nabriva Therapeutics (NASDAQ:NBRV) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research note released on Thursday morning. The firm issued a hold rating on the biotechnology company’s stock. Nabriva Therapeutics Trading Up 709,900.0 % Shares of NASDAQ NBRV opened at $1.42 on Thursday. The company has a current ratio of 0.85, a […]

Leave a Reply

Your email address will not be published.

Previous post Blue Bird (NASDAQ:BLBD) Coverage Initiated by Analysts at Needham & Company LLC
Next post FY2026 EPS Estimates for Metals Acquisition Limited Reduced by Analyst (NYSE:MTAL)